1. Introduction {#s0005}
===============

Persecutory delusions are one of the key psychotic experiences. Existing treatments for psychotic experiences, pharmacological and psychological, are only partially effective ([@bb0145; @bb0090]). Our approach to developing a much more efficacious treatment is to target the main mechanisms causing the delusions. We take a step by step approach to translation of the advances in understanding persecutory delusions ([@bb0060]), based upon an interventionist-causal model approach ([@bb0125]). One of the putative causal factors with the greatest empirical support is negative beliefs about the self ([@bb0075; @bb0135; @bb0180]). Therefore in the current study we aimed to reduce negative thoughts about the self in order to test the effect on clinical paranoia.

Negative thoughts about the self can lead to feelings of being different, apart, inferior and hence vulnerable, a perspective central to the theoretical conceptualisation of the paranoia hierarchy (see [Fig. 1](#f0005){ref-type="fig"}) ([@bb0070]). Paranoia will flourish when an individual perceives him or herself as vulnerable. Three recent systematic reviews have established that paranoia is associated with negative cognitions about the self ([@bb0095; @bb0135; @bb0180]). There is also longitudinal and experimental support. In a study of 301 patients with psychosis assessed three times over 12 months, negative cognitions about the self predicted the persistence of persecutory delusions, with little evidence of reverse causation ([@bb0045]). A study of sixty patients with persecutory delusions showed that negative beliefs about the self predicted the persistence of paranoia over the next six months ([@bb0185]). In an experimental study using virtual reality it was shown that increasing negative views of the self leads to an increase in paranoia in vulnerable individuals ([@bb0055]). There are numerous other reports of links between negative self-concepts and paranoia ([@bb0025; @bb0120; @bb0150; @bb0010]). Adverse experiences and environments will have a major contribution to the development of negative self-concepts (e.g. [@bb0165; @bb0100; @bb0030]).

The clinical implication is that reducing negative thoughts about the self will lead to reductions in persecutory delusions. Consistent with this, self-esteem interventions for patients with psychosis have also been shown to lead to improvements in positive symptoms (e.g. [@bb0140; @bb0115]). These studies have not examined persecutory delusions specifically. We set-out to reduce the short-term negative self-cognitions in patients with persistent persecutory delusions. Our view is that concepts such as negative self cognitions, self-esteem, and negative social comparison are closely related phenomena, tied to levels of depression. Therefore we measured all of these concepts. The evaluation was an early Phase II clinical trial, but with similarities to an experimental test. We used both standard CBT techniques for negative thoughts but also techniques from positive psychology to increase positive thoughts about the self ([@bb0080]); this was on the basis of clinical experience and research that shows that negative and positive affect are inversely correlated and overlap in genetic and environmental causes (e.g. [@bb0130; @bb0155]). That is, our approach was to try to diminish negative thoughts and build positive thoughts. This is consistent with [@bb0190] argument that 'positive and negative characteristics cannot logically be studied or changed in isolation'. The primary hypothesis was that a brief intervention focused on reducing negative beliefs about the self would immediately post-treatment produce reductions both in negative beliefs and in paranoia. The secondary prediction was that there would be improvements in related variables: positive beliefs about the self, comparison of self to others, self esteem, well-being, anxiety, and depression. Of course improvements in well-being and depression in this group would be valuable irrespective of effects on paranoia; almost half of patients with persecutory delusions have well-being scores in the lowest 2% of the population ([@bb0085]) and a similar proportion meet diagnostic criteria for depression ([@bb0185]). We also examined whether any improvements due to treatment would be maintained at a follow-up assessment, although at this stage of intervention development we were focussed upon immediate change with treatment.

2. Method {#s0010}
=========

2.1. Participants {#s0025}
-----------------

30 patients were recruited from Oxford Health NHS Foundation Trust. The inclusion criteria were: a current persecutory delusion as defined by [@bb0065]; scoring at least 3 on the conviction scale of the PSYRATS ([@bb0110]); the delusion had persisted for at least three months; a clinical diagnosis of schizophrenia, schizoaffective disorder or delusional disorder (i.e. a diagnosis of non-affective psychosis); negative beliefs about the self as indicated by endorsing at least one negative schematic belief on the Brief Core Schema Scale (BCSS; [@bb0040]); aged between 18 and 70; and where major changes in medication are being made, entry to the study would not occur until at least a month after stabilisation of dosage. The exclusion criteria were: a primary diagnosis of alcohol or substance dependency; organic syndrome or learning disability; a command of spoken English inadequate for engaging in therapy or the assessments; and currently having individual CBT (though previous experience of CBT was not an exclusion criterion). Recruitment into the study is summarised in the CONSORT diagram (see [Fig. 2](#f0010){ref-type="fig"}). It took place from September 2012 to March 2014 (though not continuously), with final data collection completed in May 2014. It is of note that no patient with a persecutory delusion was excluded on the basis of not endorsing at least one negative schematic belief on the BCSS.

2.2. Research design {#s0030}
--------------------

The study was a randomised controlled evaluation. Patients with persecutory delusions were randomised to the CBT intervention in addition to standard care or to standard care. Randomisation was carried out in a 1:1 ratio using varying randomised permuted blocks via a sequence obtained from [www.randomization.com](http://www.randomization.com){#ir0010}, which was conducted by a researcher independent of the recruitment and assessment process. Random allocation followed completion of the baseline assessment. Informing patients of allocation was carried out by the trial therapists, who opened an allocation envelope. Assessments were carried out by a rater, a graduate psychologist (NE), blind to allocation. Precautionary strategies included: the therapist being encouraged to consider room use and diary arrangements in the light of potential breaks of masking; patients being reminded by the assessor not to talk about treatment allocation; and, after the initial assessment, the assessor did not look at the patients\' clinical notes until the last of the ratings had been collected. If a blind was broken then another researcher within the team carried out the assessment. 28 out of 29 eight week assessments were carried out blind and all 12 week assessments were carried out blind. The assessment measures were completed at 0 weeks (baseline), 8 weeks (end of therapy), and at 12 weeks (a one month follow-up). The study had received approval from an NHS research ethics committee and was registered (ISRCTN06118265).

2.3. Planned interventions {#s0035}
--------------------------

The intervention was described to patients as having the aim of improving self-confidence, and was provided in six sessions to each individual over eight weeks. It was provided by clinical psychologists (DF, KP, BS, FW), with occasional support from a graduate psychologist (EC, RL) particularly for helping patients with tasks between sessions (e.g. going outside to do an activity). The strategies used were indicated in the literature to be effective at reducing negative beliefs about the self and boosting positive beliefs (and did not challenge or review the delusion itself). The strategies are described in detail in *You Can Be Happy* ([@bb0080]), which was provided for a number of therapy patients. The intervention is designed to provide clear and simple messages for patients to take into their day-to-day lives. There was an explicit agenda made with the patient to focus upon three areas: 1. negative thoughts about the self, 2. positive activities, and 3. positive thoughts about the self. Negative thoughts about the self were normalised, made understandable in the context of a person\'s experiences, and reviewed. Where voices were encouraging negative thoughts about the self the patient was helped to see this as a poor source of information and to disengage attention. Written accounts by other patients were provided. Activities were structured around the concept of five-a-day for mental well-being ([@bb0035]): connect, be active, take notice, keep learning, and give. The aim was to increase the number of these activities a patient did during the week. Positive thoughts were encouraged by reviewing the person\'s strengths, savouring, and keeping a diary of positive events. Positive music and pictures were also used. The patients wanted to focus on improving their self-confidence but in the instances where paranoid thoughts were brought up then the therapist would empathise with the distress and the self-confidence techniques would be framed as a way of building up strength to help deal with the difficult events occurring in the person\'s life. Tasks were set between sessions and there were supportive telephone calls or texts, and a graduate psychologist could visit to help with carrying out of an activity. Throughout the intervention the person\'s main negative self-belief and a positive self-belief were measured to monitor progress. All trial patients continued to receive standard care. Standard care was delivered according to national and local service protocols and guidelines. It usually consisted of prescription of anti-psychotic medication, visits from a community mental health worker, and regular outpatient appointments with a psychiatrist.

2.4. Primary outcome measures {#s0040}
-----------------------------

### 2.4.1. Brief Core Schema Scales (BCSS) ([@bb0040]) {#s0045}

The self-report BCSS, developed with non-clinical and psychosis groups, has 24 items assessing negative and positive beliefs about the self and others each rated on a five-point scale (0--4). Higher scores reflect greater endorsement of items. The sub-scales of interest in the current study were negative beliefs about self, which contains six items (e.g. 'I am unloved' 'I am worthless' 'I am weak'), and positive beliefs about self, which contains six items (e.g. 'I am respected' 'I am valuable' 'I am talented').

### 2.4.2. Green et al. Paranoid Thoughts Scale (GPTS; [@bb0105]) {#s0050}

The GPTS is a thirty-two item self-report measure of paranoid thinking, designed for both clinical and non-clinical populations. Part A assesses ideas of reference (e.g. 'It was hard to stop thinking about people talking about me behind my back') and Part B assesses ideas of persecution (e.g. 'I was convinced there was a conspiracy against me'). Each item is rated on a 5-point scale. It was completed for the time period of the past fortnight. Higher scores indicate greater levels of paranoid thinking.

2.5. Secondary outcome measures {#s0055}
-------------------------------

### 2.5.1. Warwick-Edinburgh Mental Well-being Scale (WEMWBS) ([@bb0175]) {#s0060}

The WEMWBS is a fourteen item scale assessing well-being over the past fortnight. Each item is rated on a 1 (none of the time) to 5 (all of the time) scale, and therefore the total score can range from 14 to 70, with higher scores indicating a greater level of well-being. Example items are: I\'ve been feeling optimistic about the future; I\'ve been feeling useful; I\'ve been feeling relaxed; I\'ve been feeling good about myself; I\'ve been feeling confident; I\'ve been feeling loved; and I\'ve been feeling cheerful. The scale has high test-test reliability and criterion validity with other wellbeing scales.

### 2.5.2. Social Comparison Scale ([@bb0005]) {#s0065}

This measure comprises eleven bipolar scales, to which we added eight further items: Inferior--superior, Incompetent--competent, unlikeable--likeable, left out--accepted, different--same, untalented--more talented, weaker--stronger, unconfident--more confident, undesirable--more desirable, unattractive--more attractive, outsider--insider, powerless--powerful, unrespected--respected, foolish--sensible, odd--normal, a failure--a success, low in self esteem--high in self esteem, a bad person--a good person, and unlike other people--like other people. Each was rated on a 0--100 scale. Cronbach\'s alpha for the full scale at each assessment time point was .93, .94, and .97, respectively. Higher scores indicate a more positive view of the self in relation to others.

### 2.5.3. Psychotic Symptom Rating Scales---Delusions (PSYRATS) ([@bb0110]) {#s0070}

The PSYRATS-Delusions scale is a six item multidimensional measure. It assesses the conviction, preoccupation, distress and disruption associated with delusions. Symptoms over the last week are rated. Higher scores indicate greater severity.

### 2.5.4. Robson Self-Concept Questionnaire (RSQ) ([@bb0160]) {#s0075}

This is a 30 item self-report scale, with each item rated on a 0 (completely disagree) to 7 (completely agree) scale. Higher scores indicate higher self-esteem.

### 2.5.5. Beck Anxiety Inventory (BAI) ([@bb0015]) {#s0080}

The BAI is a self-report 21-item, four point (0--3) scale for the assessment of anxiety over the past week. Higher scores indicate higher levels of anxiety.

### 2.5.6. Beck Depression Inventory-II (BDI) ([@bb0020]) {#s0085}

The BDI-II is a self-report 21-item, four point scale (0--3) for the assessment of depression over the past fortnight. Higher scores indicate higher depression.

2.6. Adverse events {#s0090}
-------------------

During the trial any adverse event that came to our attention was recorded. Medical notes were also examined at the end of the trial for the following events pre-specified as adverse: 1. All deaths. 2. Suicide attempts. 3. Serious violent incidents. 4. Admissions to secure units. 5. Formal complaints about therapy. Psychiatric hospital admissions were also recorded.

2.7. Statistical analysis {#s0095}
-------------------------

All analyses were carried out using Stata version 13 ([@bb0170]). All main analyses were carried out at the end of the last follow-up assessments and were based on the intention-to-treat principle. Analysis of covariance was carried out for each outcome variable, separately for 8 and 12 week assessment points. The effect of group allocation was tested, controlling for the appropriate baseline measure. At this stage of evaluation, confidence intervals for change and effect sizes are of most interest, not probability values. No formal power calculations were considered relevant. Effect sizes were calculated using Cohen\'s *d*, taking the estimated coefficient of treatment allocation from the ANCOVA divided by the pooled baseline standard deviation. The study target sample size was thirty patients, which would allow detection of large clinical effects.

3. Results {#s0015}
==========

3.1. Basic demographic and clinical data {#s0100}
----------------------------------------

[Table 1](#t0005){ref-type="table"} provides detail of basic demographic and clinical information about the patients. The majority of patients had a clinical diagnosis of schizophrenia, they were all outpatients, and all were taking neuroleptic medication.

3.2. Up-take of therapy {#s0105}
-----------------------

All of the patients received the intervention. Eleven patients in the treatment group received six CBT sessions, and the intervention was provided in seven sessions for four patients. Comments from patients who had the intervention are provided in [Table 2](#t0010){ref-type="table"}.

3.3. Outcomes {#s0110}
-------------

The scores of the allocation groups for each assessment at each time point are displayed in [Table 3](#t0015){ref-type="table"}. It can be seen that at posttreatment eight of the nine assessment variables showed signs of improvement with treatment, ranging from small to large effects. Five out of nine posttreatment tests reached statistical significance, with the treatment group benefiting in each case. For the primary measures there was a small effect size reduction in negative beliefs about the self and a moderate effect size reduction in paranoia, neither of which was statistically significant. For the secondary outcomes there were notable improvements in psychological well-being, positive beliefs about the self, self-esteem, social comparison, and depression. Anxiety levels were slightly lower in the control group posttreatment. No benefits of treatment were maintained at the 12 week assessment.

3.4. Admissions and adverse events {#s0115}
----------------------------------

From medical notes it was found that one patient in each allocation group had an admission to psychiatric hospital during the trial. One patient, in the control group, made a suicide attempt. There were no deaths, serious violent incidents, admissions to forensic wards, or formal complaints about therapy.

4. Discussion {#s0020}
=============

There is clear evidence from longitudinal and experimental studies that negative cognitions about the self are a putative causal factor in paranoia (e.g. [@bb0045; @bb0150; @bb0185; @bb0055]). We set-out to test this directly in patients with persecutory delusions. The interest at this stage was the immediate effects of targeting cognitions about the self. We did not try to determine which specific intervention techniques may change the mechanism. This focus on mechanism change is similar to an experimental study, though closest to a Phase II early clinical trial. The evaluation proved feasible, acceptable, and had good methodological rigour for an early stage test: assessments were blind, all patients attended all therapy sessions, and there was an exceptionally high follow-up rate. There were important gains for the patients with CBT in psychological well-being, depression, positive beliefs about the self, self-esteem, and social comparison. There were small improvements in negative beliefs about the self. As predicted there were also improvements in overall levels of paranoia and the main persistent persecutory delusions, although these did not reach statistical significance. Our view is that this indicates the potential value of targeting negative cognitions in patients with persecutory delusions.

The patients all had delusions that had persisted for a considerable period of time despite medication. Other psychotic experiences such as auditory hallucinations were very common. The therapy was very well-received: all patients attended all the sessions. Indeed there was a general readiness of patients to attend further treatment sessions. We found that positive psychology techniques and activity were most used, with much less work directly on negative views about the self. Patients appreciated a shift of focus away from their problems towards their strengths. The improvements in psychological well-being during the trial are notable and are clearly important in their own right as an outcome. This work is likely to have wider applicability to patients with psychosis. Nonetheless it may be argued that this therapy focus led to less change in negative self cognitions, which may have the closest connections to paranoid ideation. Measurement issues may also be important here, since the Brief Core Schema Scale ([@bb0040]) was not developed as an outcome scale, whereas the Warwick Edinburgh Mental Well-Being Scale ([@bb0175]) is well-received by patients. Further, we are struck by the gains not being maintained. Although our focus was on short-term change, we still expected gains to last. Our other brief interventions have maintained treatment gains over several months ([@bb0050]). Given the theoretical and research foundations for the link between negative self cognitions and paranoia, and the promise of the current study, we believe that this treatment development needs to be pursued. Our recommendations are that intervention needs to be lengthened, the targeting of negative cognitions and positive cognitions needs to be directly compared, and that an attention control condition would add strength to the judgements that can be reached. Negative self cognitions in patients with severe paranoia are likely to reflect deeply engrained self views which relate to appraisals of negative experiences over the life course, and may indeed be maintained by ongoing adverse experiences and social circumstances. How to improve negative cognitions in patients with paranoia is likely to prove an area of key interest in the future. We expect such treatment approaches in future clinical practice to be combined with interventions that target other key causal factors in paranoia ([@bb0060]).
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###### 

Basic demographic and clinical data.

  -------------------------------------------------------------------------------------------------------------
                                                        Treatment group (*n* = 15)   Control group (*n* = 15)
  ----------------------------------------------------- ---------------------------- --------------------------
  Mean age in years (SD)                                41.9 (11.5)                  41.5 (13.1)

  Male; female                                          11; 4                        9; 6

  Ethnicity:                                                                         

  White                                                 15                           13

  Other                                                 0                            2

  Employment status:\                                   13                           13
  unemployed                                                                         

  Part-time employed                                    0                            0

  Full-time employed                                    1                            1

  Self employed                                         0                            0

  Retired                                               0                            0

  Student                                               1                            1

  Diagnosis:\                                           12                           10
  schizophrenia                                                                      

  Schizo-affective disorder                             2                            4

  Delusional disorder                                   0                            1

  Psychosis NOS                                         1                            0

  Mean chlorpromazine equivalent medication dose (SD)   597.8 (355.6)                534.4 (424.7)
  -------------------------------------------------------------------------------------------------------------

###### 

Illustrative patient comments on the intervention.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient 1\
  "I thought it was excellent. My self-confidence has got better and I think more positively. Before, everything seemed like a really big problem and I worried a lot. I do still worry, but I tell myself I can\'t do anything about it so I write it down instead. I\'m feeling really good at the moment."

  Patient 2\
  "Things are good now. I\'m now able to help my wife more, it\'s easier to spend time with my grandchildren and I\'m much more patient. I went to see my psychiatrist last week and he said I\'m the best he\'s ever seen me. It was really helpful to talk about the personal stuff for the first time and sharing it with someone who understands. It was tough but it\'s gotta get bad before it gets better. When I spoke to my daughter she thought it was too tough, but something inside me told me to keep going. I\'m really glad I did."

  Patient 3\
  "I think I am more confident and I have a slightly different bearing. The way I feel in myself and the way I am in myself. I feel more confident, a general sense of being more confident... It really helped me to reverse the balance and swing the pendulum back. It\'s such a change to think about strengths after years of going to the doctors and saying what\'s wrong. I\'ve started giving my doctor and care co-ordinator that I meet a copy of my CV with my education, work I\'ve done and voluntary experience on. I tell them that this is the me that you don\'t see when I\'m well."
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

The outcome measure scores at each assessment time.

                                     Treatment group   Control group                                                                          
  ---------------------------------- ----------------- --------------- ------- ---- ------- ------- -------- ---------------- -------- ------ --------
  Negative self (BCSS) 0 weeks       15                11.1            6.5     15   12.5    4.3                                               
  Negative self (BCSS) 8 weeks       15                6.4             4.7     14   8.1     3.7     − 1.3    − 4.0, 1.5       − 0.95   .353   0.24
  Negative self (BCSS) 12 weeks      15                7.6             5.3     15   8.1     5.6     0.1      − 3.6, 3.9       0.07     .944   
  Paranoia (GPTS) 0 weeks            15                103.7           25.2    15   117.8   24.1                                              
  Paranoia (GPTS) 8 weeks            15                82.3            32.2    14   106.3   203     − 14.9   − 33.1, 3.3      − 1.68   .105   0.59
  Paranoia (GPTS) 12 weeks           15                84.4            31.6    15   98.6    28.3    − 4.8    − 24.9, 15.2     − 0.50   .624   
  Positive self (BCSS) 0 weeks       15                4.1             4.4     15   3.7     4.0                                               
  Positive self (BCSS) 8 weeks       15                8.6             4.4     14   4.4     2.8     4.1      1.6, 6.7         3.33     .003   1.00
  Positive self (BCSS) 12 weeks      15                7.3             5.4     15   6.3     4.8     0.7      − 2.5, 3.9       0.45     .657   
  Social comparison (SCS) 0 weeks    15                433.8           287.3   15   408.1   193.9                                             
  Social comparison (SCS) 8 weeks    15                903.7           326.8   14   678.1   239.1   211.8    24.3, 399.4      2.32     .028   0.88
  Social comparison (SCS) 12 weeks   15                754.8           406.6   15   636.0   311.9   104.6    − 152.2, 361.3   0.84     .411   
  Delusion (PSYRATS) 0 weeks         15                18.4            2.9     15   18.1    2.9                                               
  Delusion (PSYRATS) 8 weeks         15                14.3            6.0     14   16.7    3.3     − 2.6    − 5.9, 0.7       − 1.64   .113   0.91
  Delusion (PSYRATS) 12 weeks        15                15.1            4.9     15   13.7    5.4     1.0      − 2.1, 4.2       0.68     .502   
  Self esteem (RSQ) 0 weeks          15                73.9            26.3    15   70.0    23.1                                              
  Self esteem (RSQ) 8 weeks          15                99.9            21.6    14   82.9    25.6    15.2     3.0, 27.4        2.56     .017   0.62
  Self esteem (RSQ) 12 weeks         15                95.3            25.9    15   83.1    30.9    9.0      − 6.5, 24.5      1.20     .242   
  Well-being (WEMWBS) 0 weeks        15                30.3            6.4     15   30.1    6.6                                               
  Well-being (WEMWBS) 8 weeks        15                41.0            7.2     14   33.5    7.3     7.4      2.2, 12.6        2.94     .007   1.16
  Well-being (WEMWBS) 12 weeks       15                39.4            10.6    15   33.3    9.7     6.0      − 1.0, 13.0      1.76     .089   
  Anxiety (BAI) 0 weeks              15                28.8            15.4    15   25.1    7.6                                               
  Anxiety (BAI) 8 weeks              15                23.6            12.8    14   19.4    8.1     2.1      − 4.4, 8.7       0.67     .507   − 0.21
  Anxiety (BAI) 12 weeks             15                22.9            15.3    15   21.5    7.1     − 1.8    − 6.5, 3.0       − 0.76   .452   
  Depression (BDI) 0 weeks           15                32.1            11.8    15   35.1    8.4                                               
  Depression (BDI) 8 weeks           15                21.3            9.9     14   29.1    9.0     − 6.9    − 13.3, − 0.4    − 2.19   .037   0.68
  Depression (BDI) 12 weeks          15                22.9            12.6    15   27.3    9.5     − 2.3    − 9.0, 4.4       − 0.70   .492   
